Summit Incurs In-Line Q4 Loss, Inks Collaboration Deal With Pfizer

Summit Therapeutics (SMMT) reported fourth-quarter 2024 loss per share of 8 cents, in line with the Zacks Consensus Estimate. In the year-ago period, the company incurred a loss of 5 cents per share.The reported loss included stock-based compensation expenses. Excluding these expenses, the adjusted loss per share was 7 cents, wider than the year-ago adjusted loss of 4 cents.As the company lacks any marketed product in its portfolio, it did not record quarterly revenues.See the Zacks Earnings Calendar to sta ...